Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & Administrative
Others
Ratios

AC Immune (ACIU) EPS (Weighted Average and Diluted) (2016 - 2017)

Historic EPS (Weighted Average and Diluted) for AC Immune (ACIU) over the last 3 years, with Q3 2019 value amounting to $19.8 million.

  • AC Immune's EPS (Weighted Average and Diluted) changed N/A to $19.8 million in Q3 2019 from the same period last year, while for Sep 2019 it was $19.8 million, marking a year-over-year change of. This contributed to the annual value of -$0.58 for FY2024, which is 1931.11% up from last year.
  • As of Q3 2019, AC Immune's EPS (Weighted Average and Diluted) stood at $19.8 million.
  • AC Immune's 5-year EPS (Weighted Average and Diluted) high stood at $19.8 million for Q3 2019, and its period low was -$25.2 million during Q2 2019.
  • In the last 3 years, AC Immune's EPS (Weighted Average and Diluted) had a median value of -$0.1 in 2016 and averaged -$1.1 million.
  • Over the last 5 years, AC Immune's EPS (Weighted Average and Diluted) had its largest YoY gain of 2153.88% in 2016, and its largest YoY loss of 2153.88% in 2016.
  • Quarter analysis of 3 years shows AC Immune's EPS (Weighted Average and Diluted) stood at -$0.12 in 2015, then grew by 21.54% to -$0.1 in 2016, then soared by 20804582623.12% to $19.8 million in 2019.
  • Its EPS (Weighted Average and Diluted) stands at $19.8 million for Q3 2019, versus -$25.2 million for Q2 2019 and -$0.1 for Q4 2016.